Cell and gene therapy

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

DDW Highlights podcast: New episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

This week in drug discovery (3-7 July)  

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More

#News

#Artificial intelligence (AI) #Cell and gene therapy #Machine learning #Monoclonal antibodies #mRNA #Precision medicine

Right on target: The shift to precision pharmaceuticals

By DDW Editor Reece Armstrong. If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World, it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Artificial intelligence (AI), gene editing, synthetic… Read More

#Exclusive Content

Woman uses Digital Glucose meter
#allogeneic cell therapies #Cell and gene therapy #Diabetes #FDA #Type 1 diabetes

FDA approves first cellular therapy for type 1 diabetes

The US Food and Drug Administration has approved CellTrans’ Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. Lantidra is approved for the treatment of adults with type 1 diabetes who are unable… Read More

#News #Trending News

#BioMarin Pharmaceuticals #Cell and gene therapy #FDA #Gene therapy #Haemophilia

One-time gene therapy for haemophilia A gets FDA green light

The US Food and Drug Administration (FDA) has approved the first gene therapy for adults with severe haemophilia A. BioMarin’s Roctavian (valoctocogene roxaparvovec-rvox) has been approved for the treatment of adults with severe haemophilia A (congenital factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL) without antibodies to adeno-associated… Read More

#News #Regulatory #Trending News

#Cell and gene therapy #Funding #Microfluidics

€16.5m to advance automated, microfluidic CGT therapy 

Astraveus, providers of modular, microfluidic cell foundries for cell and gene therapy (CGT) manufacturing, has completed an oversubscribed €16.5 million Series Seed financing led by AdBio partners, co-syndicated with M Ventures, Johnson & Johnson Innovation – JJDC Inc., and Bpifrance Large Venture.  Astraveus’ Lakhesys platform is an end-to-end cell foundry… Read More

#Business & Investment #News

Drug discovery concept petri dish
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Join this exclusive DDW roundtable on drug discovery trends

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Drug development #FDA #Gene therapy

New podcast episode: DDW Highlights 26 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been… Read More

#News

#Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Drug development #FDA #Gene therapy

This week in drug discovery (19-23 June)  

News round-up for 19-23 June by DDW Digital Content Editor Diana Spencer. Advanced Therapy Medicinal Products (ATMPs) have been making the news this week. Particularly noteworthy have been the announcement of the FDA’s approval of the first gene therapy for Duchenne muscular dystrophy, and a caution… Read More

#News

Approval stamp
#AAV #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Gene therapy #Genetics / genomics #Muscular dystrophy #Sarepta Therapeutics

FDA approves first gene therapy for Duchenne muscular dystrophy

Sarepta Therapeutics’ Elevidys has become the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US. The Food and Drug Administration (FDA) has granted accelerated approval to Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus (AAV) based gene therapy for the treatment of DMD. It is approved… Read More

#News #Regulatory #Trending News

Research in genetics laboratory
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #Europe #Rare disease

Proposed EU clinical assessment rules would reject ATMPs

The proposed joint clinical assessment methodology would have rejected nearly 90% of the ATMPs currently authorised in the EU, claims the Alliance for Regenerative Medicine (ARM). According to ARM, all seven gene therapies for rare genetic diseases would have been rejected under the baseline methodologies proposed… Read More

#Editor's Choice #News

Clinical research
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Roundtable: What will have most impact on drug discovery trends?

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News

Cryo-EM
#Advanced Therapy Medicinal Products (ATMPs) #Blood products #Cell and gene therapy #Collaboration #Cryopreservation #Cyto-care.eu #Partnership #SCTbio

Companies collaborate to improve cell therapy cryopreservation

Contract development and manufacturing organisation (CDMO) SCTbio and cell therapy company Cyto-care.eu have teamed up with the aim of improving the quality of cryopreservation in Europe. The goal of the collaboration is to address the critical need for efficient collection, cryopreservation, quality control and logistics capabilities… Read More

#News

Paris
#Cell and gene therapy #Events #ISCT #new generation MSCs

ISCT 2023 key trends: redefining manufacturing 

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. The ISCT 2023 Annual Meeting took place in Paris, France from… Read More

#Exclusive Content #Regulatory

Paris
#Advanced Therapies #Cell and gene therapy #ISCT #Regulatory

ISCT 2023 key trends: regulatory changes 

The International Society for Cellular Therapy (ISCT) is a global society of clinicians, regulators, technologists, and industry partners with a shared mission to drive the translation of all cell and gene (CGT) therapies for the benefit of patients worldwide. The ISCT 2023 Annual Meeting took place in Paris, France from… Read More

#Exclusive Content #Regulatory

Medical research
#Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Cell and gene therapy #Drug development #Drug discovery #mRNA-based vaccines #Roundtable

Join our roundtable on drug discovery and development trends

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET. Join this free roundtable… Read More

Webinar date:
Sponsored by DNA Script
#News